Summary of Key Points from the Conference Call Records Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** for Q1 2026, highlighting performance disparities among companies like **Angelalign** and **Eli Lilly**, with profits exceeding 40% due to successful global operations and innovation [1][2]. Core Insights and Arguments - **Performance Disparities**: The pharmaceutical sector shows significant performance differences, with companies like **Angelalign** and **Eli Lilly** achieving over 40% profit growth, validating the logic of global operations and profit realization [1]. - **Investment Strategy**: The strategy for March 2026 shifts towards companies with strong annual report performance expectations, reducing the valuation weight of early pipeline projects, and increasing allocations to **CXO** and medical consumption sectors [1][2]. - **Haikang's Key Data Catalysts**: Haikang is expected to release critical Phase II data for CFB (IgA nephropathy) and THbeta (MASH) in H1 2026, which could lead to significant market expectations [1][4]. - **Federal Pharmaceutical's UBT251 Pipeline**: The strategic position of UBT251 is enhanced as Novo Nordisk accelerates its overseas Phase II trials, potentially narrowing the gap with similar products [1][2]. - **CXO Sector Premium**: The leading position of **WuXi AppTec** is highlighted, with a historical high discount of 10% between A/H shares, indicating strengthened competitive positioning in the medium term [1][2]. - **Medical Device Exports**: **Precision Medical** has over 60% of its orders from overseas, with expectations to increase its market share from 5% to 20% [1][2]. Additional Important Insights - **Eli Lilly's Financial Performance**: Eli Lilly reported Q1 2026 revenue of 1.5 billion, a 41.2% year-on-year increase, with net profit expected to reach approximately 600 million, reflecting a 44% growth [2][12]. - **Haikang's Pipeline Details**: Haikang's pipeline includes five major products with significant Phase II data expected in 2026, including PDE34 for COPD and oral TH beta for liver penetration [4][5]. - **Market Trends**: The overall market sentiment reflects a disconnect between stock prices and industry progress, with a focus on companies entering profit realization phases [2][3]. - **Regulatory Environment**: Changes in regulatory requirements for liver penetration may facilitate faster progression for Haikang's TH beta project [6][7]. - **Federal Pharmaceutical's Recovery Signals**: The company is expected to see recovery in its core business, with raw material prices stabilizing and animal health business growth anticipated in 2026 [7][8]. - **Medical Device Market Dynamics**: **Precision Medical** is positioned as a leader in surgical robotics, with significant growth in overseas orders and market share potential [14][15]. Conclusion The conference call provides a comprehensive overview of the pharmaceutical and medical device sectors, emphasizing the importance of innovation, global operations, and strategic positioning in navigating market challenges and opportunities. Key companies are highlighted for their strong performance and potential for future growth, particularly in the context of upcoming data releases and regulatory changes.

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 本月底法定/註冊股本總額： RMB 2,983,757,155 備註： 第 1 頁 共 11 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB ...

Core Insights - The top three companies with the highest short positions as of February 20 are China COSCO Shipping (01919) at 18.86%, CATL (03750) at 16.68%, and Ping An Insurance (02318) at 15.48% [1][2] Group 1: Top Short Positions - China COSCO Shipping (01919) has a short position of 520 million shares, representing a short ratio of 18.86% [2] - CATL (03750) has a short position of 26.0064 million shares, with a short ratio of 16.68% [2] - Ping An Insurance (02318) has a short position of 1.153 billion shares, with a short ratio of 15.48% [2] - Sunny Optical Technology (02382) has a short ratio of 15.24% [2] - Dongfang Electric (01072) has a short ratio of 15.12% [2] - ZTE Corporation (00763) has a short ratio of 14.53% [2] - Vanke (02202) has a short ratio of 14.16% [2] - Zijin Mining (02899) has a short ratio of 13.50% [2] - Hansoh Pharmaceutical (01276) has a short ratio of 13.32% [2] - WuXi AppTec (02359) has a short ratio of 12.50% [2] Group 2: Largest Increases in Short Positions - Weimob (02013) saw an increase of 0.27% in its short ratio, now at 12.43% [2] - China Duty Free Group (01880) increased by 0.25%, now at 8.92% [2] - Midea Group (00300) increased by 0.23%, now at 4.26% [2] - Meitu (01357) increased by 0.22%, now at 8.21% [2] - Xinjiang Xinxin Mining (03833) increased by 0.20%, now at 0.51% [2] - Hua Hong Semiconductor (01347) increased by 0.20%, now at 3.59% [2] - Minmetals Development (00425) increased by 0.19%, now at 2.59% [2] - China COSCO Energy (01138) increased by 0.18%, now at 6.61% [2] - Jiaxin International Resources (03858) increased by 0.17%, now at 0.25% [2] - China Railway (00390) increased by 0.17%, now at 4.61% [2] Group 3: Largest Decreases in Short Positions - Pacific Basin Shipping (02343) decreased by 0.83%, now at 4.66% [3] - Tianqi Lithium (09696) decreased by 0.66%, now at 2.25% [3] - Tiangong International (00826) decreased by 0.51%, now at 3.46% [3] - Huiju Technology (01729) decreased by 0.50%, now at 3.08% [3] - Shengye (06069) decreased by 0.44%, now at 1.63% [3] - Ganfeng Lithium (01772) decreased by 0.29%, now at 8.52% [3] - China Galaxy (06881) decreased by 0.25%, now at 3.19% [4] - Jiangxi Copper (00358) decreased by 0.22%, now at 2.32% [4] - China COSCO Shipping (01919) decreased by 0.21%, now at 18.86% [4] - Cafe de Coral (00341) decreased by 0.19%, now at 5.43% [4]

来源：第一财经 恒生指数收涨0.95%，恒生科技指数涨0.56%。新鸿基地产涨逾7%，药明生物涨逾5%，商汤涨近5%， 中国神华涨逾4%，长实集团、石药集团、药明康德涨逾3%。 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-27 | 药明康德 | 603259 | 98.01 254.83 | 2.6 | 机构专用 | 發開手落在過程貨 | | Ka | 2月27日，药明康德大宗交易成交2.6万股，成交额254.83万元，占当日总成交额的0.11%，成交价98.01 元，较市场收盘价98.01元持平。 ...

随着近期多只生物医药股靓丽业绩放榜，今日港股创新药概念也集体活跃。其中，入选了2026年格隆 汇"下注中国"十大核心资产名单的药明合联涨超8%，领涨板块，药明生物涨超5%，康方生物、云顶新 耀、诺诚健华涨超4%，石药集团、再鼎医药、药明康德涨超3%。 | 代码 | 名称 | | 涨跌幅 V | 最新价 | 总市值 | 年初至今涨跌 | | --- | --- | --- | --- | --- | --- | --- | | 02268 | 药明合联 | 0 | 8.40% | 63.250 | 795.68亿 | 4.12% | | 02269 | 药明生物 | | 5.38% | 40.340 | 1669.08 Z | 28.31% | | 09926 | 康方生物 | | 4.81% | 106.800 | 983.78亿 | -5.49% | | 01952 | 云顶新耀 | | 4.27% | 37.600 | 132.95亿 | 1.68% | | 69660 | 诺成健华 | | 4.04% | 12.090 | 213.04亿 | -1.71% | | 01093 | 石约集团 | | 3. ...

Group 1 - CXO concept stocks have shown significant gains, with WuXi AppTec (02268) rising by 7.97% to HKD 63, WuXi Biologics (02269) increasing by 4.7% to HKD 40.08, WuXi PharmaTech (603259) (02359) up by 2.28% to HKD 19.7, and Kanglong Chemical (300759) (03759) also up by 2.28% to HKD 19.7 [1] - According to a report from Citi, investor focus is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to internal AI adoption by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report highlights that leading companies in the industry may experience overselling during this market window lacking catalysts, creating attractive entry points for investors with a 3 to 12-month investment horizon [1]

每经AI快讯，2月27日，港股CXO概念股涨幅居前，药明合联(02268.HK)涨7.97%，报63港元；药明生 物(02269.HK)涨4.7%，报40.08港元；药明康德(02359.HK)涨2.28%，报19.7港元；康龙化成(03759.HK) 涨2.28%，报19.7港元。 ...

Group 1 - The core viewpoint of the article highlights the recent performance of CXO concept stocks, with notable gains in companies such as WuXi AppTec (02268) up 7.97% to HKD 63, WuXi Biologics (02269) up 4.7% to HKD 40.08, WuXi PharmaTech (02359) up 2.28% to HKD 19.7, and Kanglong Chemical (03759) also up 2.28% to HKD 19.7 [1] - According to a report from Citi, the focus of investors is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to the accelerated adoption of AI by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report emphasizes that leading companies in the industry may experience overselling during this market window lacking catalysts, creating more attractive entry points for investors with a 3 to 12-month investment horizon [1]